Varlilumab: A Deep Dive into CDX-1127 and its Mechanism Varlilumab (formerly known as compound CDX-1127) represents an innovative therapeutic agent targeting CD27. The drug's mode of action depends on binding to CD27, a transmembrane molecule essential for lymphocyte response and anti-tumor defense
{Amivantamab: A Promising Solution for c-MET Driven Cancers?
The emergence of amivantamab offers a significant development for people battling cancers with c-MET overexpression. This innovative therapeutic, a precise agent of multiple MET kinase and human epidermal growth factor receptor 2 (HER2), showed preliminary results in research studies, particularly i